Skip to main content

Published locations for Gemtuzumab ozogamycin heightens risk for toxicities with no survival benefit in de novo AML

Primary tabs

  • View
  • Get Stamp Tags
  • Published Locations

Breadcrumb

  1. Home
  3. Gemtuzumab ozogamycin heightens risk for toxicities with no survival benefit in de novo AML

User login

  • Reset your password
  • /content/gemtuzumab-ozogamycin-heightens-risk-toxicities-no-survival-benefit-de-novo-aml
  • /hematology-oncology/article/239801/aml/gemtuzumab-ozogamycin-heightens-risk-toxicities-no-survival